Pharmafile Logo

Eliquis

Bristol-Myers Squibb (BMS) building

BMS’ Opdivo defies naysayers with healthy growth

Third quarter sales of the PD1 inhibitor saw a 38% rise

- PMLiVE

Pfizer could raise ‘up to $15bn’ from consumer unit sale

Would follow in the footsteps of Novartis, Boehringer and Merck & Co if it does strike a deal

Bristol-Myers Squibb (BMS) building

NICE says OK to Opdivo for lung cancer via CDF

Comes after BMS drops the price of its PD-1 inhibitor

Cancer Research UK’s Karen Vousden to join BMS board

She will also serve on the pharma firm's Science and Technology Committee

- PMLiVE

Novartis scores but Roche misses in melanoma trials

Phase III trial combo success for Tafinlar/Mekinist “unprecedented”

Bristol-Myers Squibb (BMS) building

BMS’ Opdivo and Yervoy ace kidney cancer trial

Combined checkpoint inhibitors show improved survival versus standard therapy

Bristol-Myers Squibb (BMS) building

BMS data add to checkpoint inhibitor combo confusion

Opdivo and Yervoy meet one objective but miss another in CheckMate-214

- PMLiVE

Biotecnol taps into Cancer Research UK network for first trial

New drug hoped to have broad activity across multiple tumour types

Bristol-Myers Squibb (BMS) building

BMS boosts immuno-oncology with $2.3bn IFM buy

Boston-based group will operate as a subsidiary of BMS

- PMLiVE

BMS and Clovis join forces in PARP combo race

Duo will combine Opdivo and Rubraca in phase II and III trials to treat a variety of tumours

- PMLiVE

BMS and Clovis join forces in PARP combo race

Duo will combine Opdivo and Rubraca in phase II and III trials to treat a variety of tumours

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links